Organisation paid for research Program year 2025 Source: CMS Open Payments

Consano Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$405,388

840 payments

Through program year 2025, Consano Clinical Research is reported as receiving $405,388 in research payments, across 840 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$75,530	263
2024	Research	$56,488	13
2023	Research	$109,981	353
2022	Research	$39,354	207
2021	Research	$275	1
2020	Research	$122,160	2
2019	Research	$1,600	1

Breakdown

Who paid Research payments · program years 2019–2025

Novo Nordisk AS $199,232 581 payments
AstraZeneca Pharmaceuticals LP $120,240 1 payment
Boehringer Ingelheim International GmbH $41,986 228 payments
Alnylam Pharmaceuticals Inc. $15,149 2 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $15,053 10 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $6,677 1 payment
Pfizer Inc. $3,256 14 payments
Amgen Inc. $2,195 2 payments
Lexicon Pharmaceuticals, Inc. $1,600 1 payment

Studies the money was for Research payments · program years 2019–2025

Nn9535-4984 $121,429 501 payments
Effectiveness of Once-weekly Exenatide (BCise) Plus Dapagliflozin on 24 Hour Glucose Variability measured by CGM. A proof of concept. $120,240 1 payment
Nn8640-4467 $44,821 23 payments
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease $15,149 2 payments
phase III efficacy for obesity - with T2DM $14,618 2 payments
Nn9535-4801 $13,732 10 payments
Phase III efficacy for obesity - without T2DM $13,099 2 payments
Nn9535-4352 $12,712 11 payments
phase III efficacy for obesity with T2DM $8,542 2 payments
Phase III efficacy for obesity without T2DM $8,223 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.